What is PHIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PHIO?

P/E (TTM) is n/a and 52-week range is $0.81 to $4.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PHIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PHIO?

The company profile lists revenue (TTM) near $140K, net income (TTM) near $-550M, EPS (TTM) near $-1.39 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Phio Pharmaceuticals Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in King of Prussia, Pennsylvania, US, 11.6M shares outstanding, ISIN US71880W5013 when available from company profile and filing metadata.

Phio Pharmaceuticals Corp

$PHIO

Health Care · Biotechnology

IR Run Scenarios

$0.98

+0.59%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in King Of Prussia, Pennsylvania and currently employs 6 full-time employees. The company went IPO on 2012-05-10. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Employees

Website

phiopharma.com/

IPO

2012-05-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)